Plain-English translation of NCT04947059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After you have surgery to remove a bladder tumor, this trial tests whether a single dose of chemotherapy—either gemcitabine hydrochloride or epirubicin hydrochloride—delivered directly into your bladder can help prevent the cancer from coming back. Both medications are given as a liquid that sits in your bladder for about an hour, starting within 6 hours after your surgery. The trial wants to know which of these two treatments works better at stopping recurrence.
Bladder cancer often comes back after surgery. Research has shown that giving chemotherapy directly into the bladder right after tumor removal can reduce the chance of recurrence, but doctors don't yet know whether gemcitabine or epirubicin works better for this purpose.
You likely qualify if…
You likely don't qualify if…
You will have surgery to remove your bladder tumor. Within 6 hours after surgery, you will randomly be assigned to receive one of two medications—either gemcitabine or epirubicin—delivered directly into your bladder as a liquid instillation that stays in place for 45 to 60 minutes. Your bladder will also be continuously flushed with saline (salt water) for 24 hours after surgery. The trial will then monitor you over time to track whether your cancer comes back and how well the treatment worked.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Greece